Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
46.83M | 49.72M | 42.41M | 37.76M | 35.74M | 35.07M | Gross Profit |
24.12M | 26.07M | 21.59M | 19.32M | 19.16M | 18.01M | EBIT |
-1.47M | -269.00K | -3.53M | 137.00K | 398.00K | -756.00K | EBITDA |
551.00K | 2.79M | -5.05M | 1.35M | 2.56M | -5.42M | Net Income Common Stockholders |
-1.75M | -338.00K | -6.12M | 1.36M | 998.00K | -5.84M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
3.96M | 1.89M | 3.80M | 7.29M | 6.77M | 6.41M | Total Assets |
47.82M | 40.36M | 41.18M | 41.71M | 38.55M | 35.53M | Total Debt |
12.56M | 8.58M | 9.47M | 6.55M | 5.82M | 4.80M | Net Debt |
8.59M | 6.69M | 5.67M | -746.00K | -950.00K | -1.61M | Total Liabilities |
26.43M | 22.15M | 22.89M | 18.12M | 16.39M | 13.73M | Stockholders Equity |
21.39M | 18.21M | 18.29M | 23.59M | 22.16M | 21.79M |
Cash Flow | Free Cash Flow | ||||
-1.57M | -986.00K | -4.36M | 302.00K | -230.00K | 1.15M | Operating Cash Flow |
-1.30M | 2.00M | 49.00K | 3.29M | 1.32M | 5.38M | Investing Cash Flow |
-5.95M | -2.99M | -4.41M | -2.98M | -1.55M | -4.23M | Financing Cash Flow |
6.83M | -1.49M | -1.00M | 1.61M | -179.00K | 448.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
50 Neutral | AU$54.78M | ― | -8.08% | ― | -5.62% | -225.71% | |
$11.41B | 46.62 | 20.61% | 1.61% | ― | ― | ||
$76.11B | 26.67 | 15.38% | 1.85% | ― | ― | ||
$848.17M | 72.50 | 9.23% | ― | ― | ― | ||
79 Outperform | AU$56.78B | 27.93 | 25.23% | 0.85% | 10.54% | 38.69% | |
61 Neutral | AU$18.38M | 140.00 | -3.11% | ― | 89.13% | 69.57% |
Compumedics Limited announced a correction to its financial guidance for FY25, expecting sales orders to exceed $60 million, with reported revenues between $50 million and $55 million, which is below the previously advised $55 million. The company anticipates an EBITDA of about $3 million for FY25, down from the previously advised $5 million. Looking ahead, Compumedics confirms FY26 revenue guidance of at least $70 million, driven by the shipment of MEG orders, with an expected EBITDA of at least $9 million.
Compumedics Limited has secured a significant contract worth $1 million for its Somfit device with a leading pharmaceutical Contract Research Organisation in the USA. This sale is part of Compumedics’ strategy to expand beyond the home sleep testing market into pharmaceutical clinical trials, leveraging Somfit’s ability to directly track brain signals for accurate sleep architecture analysis. The contract highlights the company’s strong growth in the USA, with sales orders reaching $12 million this year, a 130% increase from the previous year. Compumedics anticipates continued growth, projecting sales orders over $60 million for FY25, although revenue and EBITDA expectations have been adjusted due to the rapid business expansion.